A review of clinical experience with paclitaxel extravasations.
Paclitaxel is a novel anti-neoplastic with a wide spectrum of activity in various malignant tumors. Extravasation of chemotherapy drugs is a widely feared adverse event in oncology patients. A Medline search between 1966 and October 2002 was conducted to identify case reports related to paclitaxel extravasation, as well as a bibliography screening of identified papers. The goal of this work is to summarize the available reports of paclitaxel extravasation and assess its vesicant potential. Additionally, management strategies for extravasation events due to paclitaxel are assessed.
Stanford
Brad L
BL
School of Pharmacy, Texas Tech University Health Sciences Center, 3601 4th Street, MS 8162, Lubbock, TX 79430, USA. brad.stanford@ttuhsc.edu
Hardwicke
Fred
F
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D005119:Extravasation of Diagnostic and Therapeutic Materials; D006801:Humans; D007275:Injections, Intravenous / Q000009:adverse effects; D017239:Paclitaxel / Q000009:adverse effects*; D011785:Quality Assurance, Health Care
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel